Active trials
Read more about the active trials with completed enrollment that MedVadis Research is involved with. Contact us anytime if you would like to volunteer or have any questions.
Adult Migraine
Study ID 273
The MONARCH (Multicenter Occipital Neuralgia and Cervicogenic Headache) Case Series Study: Treatment of Head Pain with the SPRINT® Peripheral Nerve Stimulation (PNS) System
The purpose of this study is to learn if pain can be relieved by delivering small amounts of electricity (called "electrical stimulation") to the nerves at the top of the neck. This study will use a device called the SPRINT® PNS System. PNS stands for peripheral nerve stimulation (PNS). This device is cleared by the FDA for up to 60 days of use for relief of chronic or acute pain.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
ALS
No Results Found.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Alzheimer’s Disease
Study ID 251
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
"The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. Trial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up."
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 60 Years to 85 Years
Enrollment Complete!
Study ID 257
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 65 Years to 80 Years
Enrollment Complete!
Study ID 274
Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 60 Years to 85 Years
Enrollment Complete!
Study ID 282
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer’s Disease
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 55 Years to 85 Years
Enrollment Complete!
Study ID 298
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 55 Years to 80 Years
Enrollment Complete!
Chronic Low Back Pain
No Results Found.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Diabetic Neuropathy
Study ID 279
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Obesity
Study ID 279
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 280
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 281
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4)
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 278
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Gout
No Results Found.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Chronic Knee Pain
Study ID 278
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 281
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4)
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!